These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 10417749

  • 41. Treatment of stingray injury with topical becaplermin gel.
    Baldinger PJ.
    J Am Podiatr Med Assoc; 1999 Oct; 89(10):531-3. PubMed ID: 10546426
    [Abstract] [Full Text] [Related]

  • 42. Diabetic foot ulcers treated with becaplermin and TheraGauze, a moisture-controlling smart dressing: a randomized, multicenter, prospective analysis.
    Landsman A, Agnew P, Parish L, Joseph R, Galiano RD.
    J Am Podiatr Med Assoc; 2010 Oct; 100(3):155-60. PubMed ID: 20479444
    [Abstract] [Full Text] [Related]

  • 43. The use of becaplermin (rhPDGF-BB) gel for chronic nonhealing ulcers. A retrospective analysis.
    Mandracchia VJ, Sanders SM, Frerichs JA.
    Clin Podiatr Med Surg; 2001 Jan; 18(1):189-209, viii. PubMed ID: 11344978
    [Abstract] [Full Text] [Related]

  • 44. Differential effects of platelet-derived growth factor BB in accelerating wound healing in aged versus young animals: the impact of tissue hypoxia.
    Wu L, Brucker M, Gruskin E, Roth SI, Mustoe TA.
    Plast Reconstr Surg; 1997 Mar; 99(3):815-22; discussion 823-4. PubMed ID: 9047202
    [Abstract] [Full Text] [Related]

  • 45. Response of ulcerated perineal hemangiomas of infancy to becaplermin gel, a recombinant human platelet-derived growth factor.
    Metz BJ, Rubenstein MC, Levy ML, Metry DW.
    Arch Dermatol; 2004 Jul; 140(7):867-70. PubMed ID: 15262700
    [Abstract] [Full Text] [Related]

  • 46. Addendum: Commentary on becaplermin gel (Regranex) for hemangiomas.
    Frieden IJ.
    Pediatr Dermatol; 2008 Jul; 25(6):590. PubMed ID: 19067861
    [No Abstract] [Full Text] [Related]

  • 47. Use of becaplermin in the closure of pharyngocutaneous fistulas.
    Jakubowicz DM, Smith RV.
    Head Neck; 2005 May; 27(5):433-8. PubMed ID: 15776464
    [Abstract] [Full Text] [Related]

  • 48. Topical becaplermin improves outcomes in work related fingertip injuries.
    Freedman BM, Oplinger EH, Freedman IS.
    J Trauma; 2005 Oct; 59(4):965-8. PubMed ID: 16374289
    [Abstract] [Full Text] [Related]

  • 49. Topical platelet-derived growth factor vs placebo therapy of diabetic foot ulcers offloaded with windowed casts: a randomized, controlled trial.
    Ma C, Hernandez MA, Kirkpatrick VE, Liang LJ, Nouvong AL, Gordon II.
    Wounds; 2015 Apr; 27(4):83-91. PubMed ID: 25855851
    [Abstract] [Full Text] [Related]

  • 50. Use of becaplermin gel and Kollagen Medifil particles.
    Tomaselli NL.
    J Wound Ostomy Continence Nurs; 2000 Nov; 27(6):319-20. PubMed ID: 11096412
    [No Abstract] [Full Text] [Related]

  • 51. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. Diabetic Ulcer Study Group.
    Steed DL, Donohoe D, Webster MW, Lindsley L.
    J Am Coll Surg; 1996 Jul; 183(1):61-4. PubMed ID: 8673309
    [Abstract] [Full Text] [Related]

  • 52. Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study.
    Lyons TE, Miller MS, Serena T, Sheehan P, Lavery L, Kirsner RS, Armstrong DG, Reese A, Yankee EW, Veves A.
    Am J Surg; 2007 Jan; 193(1):49-54. PubMed ID: 17188087
    [Abstract] [Full Text] [Related]

  • 53. The future of recombinant growth factors in wound healing.
    Robson MC, Mustoe TA, Hunt TK.
    Am J Surg; 1998 Aug; 176(2A Suppl):80S-82S. PubMed ID: 9777977
    [Abstract] [Full Text] [Related]

  • 54. Pharmacotherapy of lower limb diabetic ulcers.
    Temple ME, Nahata MC.
    J Am Geriatr Soc; 2000 Jul; 48(7):822-8. PubMed ID: 10894324
    [Abstract] [Full Text] [Related]

  • 55. Immunomodulatory role of Tinospora cordifolia as an adjuvant in surgical treatment of diabetic foot ulcers: a prospective randomized controlled study.
    Purandare H, Supe A.
    Indian J Med Sci; 2007 Jun; 61(6):347-55. PubMed ID: 17558098
    [Abstract] [Full Text] [Related]

  • 56. Recombinant human platelet-derived growth factor for refractory nondiabetic ulcers: a retrospective series.
    Harrison-Balestra C, Eaglstein WH, Falabela AF, Kirsner RS.
    Dermatol Surg; 2002 Aug; 28(8):755-9; discussion 759-60. PubMed ID: 12174074
    [Abstract] [Full Text] [Related]

  • 57. [Approval for recombinant growth factor. Since January 2000, patients with diabetic foot ulcers can be treated with the growth factor becaplermin (Regranex), manufactured with genetic technology].
    Fruhstorfer B.
    Internist (Berl); 2000 Jan; 41(1):A38. PubMed ID: 10712088
    [No Abstract] [Full Text] [Related]

  • 58. Benefit-risk assessment of becaplermin in the treatment of diabetic foot ulcers.
    Papanas N, Maltezos E.
    Drug Saf; 2010 Jun 01; 33(6):455-61. PubMed ID: 20486728
    [Abstract] [Full Text] [Related]

  • 59. Efficacy of topical recombinant human platelet-derived growth factor for treatment of diabetic lower-extremity ulcers: Systematic review and meta-analysis.
    Zhao XH, Gu HF, Xu ZR, Zhang Q, Lv XY, Zheng XJ, Yang YM.
    Metabolism; 2014 Oct 01; 63(10):1304-13. PubMed ID: 25060693
    [Abstract] [Full Text] [Related]

  • 60. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot. A pilot, randomized, double-blind, placebo-controlled study.
    Richard JL, Parer-Richard C, Daures JP, Clouet S, Vannereau D, Bringer J, Rodier M, Jacob C, Comte-Bardonnet M.
    Diabetes Care; 1995 Jan 01; 18(1):64-9. PubMed ID: 7698050
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.